 		   Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.

For the period, ADAC reported revenues of $68.4 million, a 24%increase over the $55 million in sales reported for the firstquarter of 1996. Net income grew 44% to $5.1 million, comparedwith $3.5 million in the same period of 1996. ADAC also reportedrecord bookings of $82 million, adding $13 million to its backlog.

ADAC said the revenue growth was due to a 10% increase in servicerevenue and a 30% increase in product revenue. Product gross marginsgrew 3.7% to 41.8% in the period. ADAC also began volume shipmentsof its Molecular Coincidence Detection (MCD) high-energy imagingtechnique in the quarter.

 CT modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of CT across the healthcare continuum, from various cancer screenings, such as lung and colon, to cardiothoracic imaging, to appendicitis, and more.

Nuclear medicine vendor ADAC Laboratories enjoyed a banner firstquarter of fiscal 1997 (end-December). The Milpitas, CA, firmlast week reported quarterly financial results that indicateddouble-digit increases in both net income and revenues.For the

ADAC&#146;s Q1 profits and revenues surge

ADACs Q1 profits and revenues surge